Uruguay Medical Device Registration in 2026: Classification, UDI, and MERCOSUR Updates

Overview: Medical Device Regulation in Uruguay

Medical Device Classification in Uruguay

Uruguay follows the MERCOSUR four-class risk-based system (Class I through IV), with IVDs classified A through D based on individual and public health risk. In January 2025, Argentina officially adopted GMC Resolution No. 25/21, the new MERCOSUR Technical Regulation for the Registration of Medical Products, replacing the previous GMC Resolution No. 40/00. This regulation standardizes classification requirements and documentation across MERCOSUR countries and introduces recognition of foreign registration data to expedite approvals for products already cleared in other MERCOSUR or reference markets.

Within MSP, medical device registrations are handled by the Unidad de Medicamentos y Acreditación de Laboratorios (UNIMED), which is the operational point of contact for submission queries and registration management. Manufacturers and their Authorized Representatives should direct all pre-submission and registration correspondence to UNIMED rather than to MSP generally.

While Uruguay has not yet published a formal adoption timeline for GMC 25/21 equivalent to Argentina’s, the resolution represents the regional direction of travel. Manufacturers should prepare documentation that aligns with the updated MERCOSUR classification and technical requirements now, particularly around structured technical documentation, to avoid rework as Uruguay’s adoption progresses.

Accurate classification remains the foundational step before dossier preparation. Misclassification is one of the most common causes of registration delays in Uruguay.

Uruguay Medical Device Registration Process

Step 1: Appoint an Authorized Representative Foreign manufacturers must appoint a locally established Authorized Representative (AR) in Uruguay. The AR holds the registration, is legally responsible for compliance, vigilance reporting, and MSP communication, and must be established within Uruguay. A Certificate of Free Sale (CFS) issued by the competent authority of the country of origin is also required as part of the registration dossier. Manufacturers should factor CFS procurement time into their project timelines, this is a frequently overlooked early step. A notarized and legalized Power of Attorney granted by the foreign manufacturer to the local representative is required before submission can proceed. This document takes time to apostille or legalize depending on the manufacturer’s country of origin, factor this into your project timeline alongside CFS procurement.

Step 2: Prepare the Technical Dossier Documentation requirements align with MERCOSUR technical regulations and increasingly reflect STED-aligned structured documentation principles. Key components include: administrative forms; device description and intended use; ISO 14971-compliant risk management documentation; verification and validation data; clinical evaluation data where required; ISO 13485 certificate; GMP evidence; and Spanish-language labeling and IFU. Note that Spanish labeling must be prepared at the outset, not as a final step, as translation quality frequently causes delays at the MSP review stage. The primary legal instruments governing dossier requirements in Uruguay are Decree 3/008 for medical devices, supplemented by MSP resolutions and ordinances, and Decree 521/984 governing manufacturer and importer authorization. These sit beneath the MERCOSUR technical regulation layer and govern the administrative requirements specific to Uruguay

Steps 3–5: Submission, Review, and Approval Submissions are made via the VUCE national single window system or MSP electronic platforms. Uruguay’s broader digital health infrastructure has been developing since 2012 when the government launched Salud.uy, its nationally integrated digital health system, and the transition toward digital regulatory submissions is part of this broader modernization trajectory. Manufacturers should confirm with their Authorized Representative which platform applies to their device class at the time of submission, as digital submission capabilities continue to expand. Review timelines in Uruguay typically run 6–12 months, varying by device class and submission completeness. Registration certificates are valid for 5 years, with renewal required prior to expiration. Several companies have expressed frustration with Uruguay’s registration process, citing long timelines and high costs, some have opted not to bring their full product suite to Uruguay given regulatory difficulties and the market’s relative size. Thorough dossier preparation and an experienced AR are the most effective ways to minimize these friction points.

Quality Management System (QMS) Requirements

Uruguay recognizes ISO 13485:2016 certification and MERCOSUR GMP (Buenas Prácticas de Fabricación — BPF) compliance. MERCOSUR quality standards, Buenas Prácticas de Fabricación (BPFs), are based on ISO 9001 and FDA GMPs, and increasingly align with ISO 13485 as the regional standard for medical device QMS. Manufacturers holding current ISO 13485 certification will find their QMS documentation maps well to BPF requirements with targeted additions. MSP may also request additional GMP evidence, particularly for higher-risk Class III and IV devices and Authorized Representatives are subject to compliance oversight covering import/distribution controls, vigilance management, and complaint handling.

Manufacturers should ensure their ISO 13485 certificates are current (typically valid for 3 years) and that GMP documentation is organized for efficient review. For manufacturers holding FDA QSR or EU MDR QMS certifications, much of the underlying documentation can be adapted for Uruguay with targeted additions, reducing the burden of building a Uruguay-specific compliance package from scratch.

UDI Requirements in Uruguay

Uruguay is implementing UDI in alignment with MERCOSUR Resolution GMC 07/24, adopted in 2024. This resolution establishes the regional framework for UDI implementation across MERCOSUR member states, creating a harmonized approach to device traceability that mirrors international standards developed by IMDRF.

Implementation is phased, beginning with higher-risk Class III and IV devices. Manufacturers should prepare by: understanding UDI carrier requirements (barcode or RFID on device labeling); confirming their GUDID or equivalent issuing agency registration; and monitoring MSP guidance for Uruguay-specific database submission obligations and class-by-class implementation timelines as enforcement expands.

Early preparation is strongly recommended. The MERCOSUR UDI framework is modeled on global approaches, manufacturers already UDI-compliant for FDA or EU markets will find significant overlap in the underlying requirements, making adaptation more efficient than building from scratch.

Post-Market Surveillance and Vigilance

Uruguay has strengthened post-market expectations in recent years, with MSP increasingly aligned with IMDRF vigilance reporting principles. Manufacturers and Authorized Representatives must: report serious adverse events within regulatory timelines; notify MSP prior to executing Field Safety Corrective Actions (FSCAs); maintain traceability and distribution records; and retain documentation for extended retention periods. Non-compliance may result in administrative fines, suspension of registration, or market withdrawal; enforcement is active, not nominal.

The Authorized Representative plays a central operational role in vigilance. Since the AR holds the registration and is the MSP’s primary contact, manufacturers should ensure their AR has the operational infrastructure to manage adverse event reporting and FSCA notifications in real time, not just on a periodic basis.

Clinical Investigation Requirements

Clinical investigations may be required for:

• Higher-risk devices
• Novel technologies
• Devices lacking sufficient clinical evidence

Requirements include:

• Ethics Committee approval
• Compliance with Good Clinical Practice
• MSP authorization prior to study initiation
• Potential regulatory inspections

Structured clinical evaluation documentation is increasingly expected.

Key Regulatory Trends in 2025–2026

Manufacturers should monitor the following active developments:

MERCOSUR GMC 25/21 regional adoption: Argentina formally adopted GMC Resolution 25/21 in January 2025, standardizing classification and documentation requirements and introducing recognition of foreign registration data across MERCOSUR. Uruguay is expected to follow as regional harmonization progresses, manufacturers should align documentation to GMC 25/21 standards now.

UDI expansion: MERCOSUR Resolution GMC 07/24 is rolling out across member states. Higher-risk devices should be UDI-ready; lower-risk class implementation timelines are expected to follow.

Digitalization of submissions: Uruguay continues transitioning toward greater digital submission capabilities via the VUCE national single window. Manufacturers should monitor MSP announcements for electronic submission process updates.

Market growth: Medical equipment imports into Uruguay grew 8.9% in 2024, driven by an aging population and rising chronic disease burden, with the U.S. as the largest supplier at 31.4% of imports. This growth trend reinforces Uruguay’s increasing commercial attractiveness for medical device companies.

Strengthened post-market oversight: MSP is increasingly active in post-market enforcement, aligning with IMDRF principles on vigilance and risk-based surveillance.

Uruguay’s digital health ecosystem expansion: Uruguay’s healthcare sector accounts for approximately 9% of GDP, with projections anticipating a rise to roughly 10% by 2027, driven by substantial investment in technology and modernization. The national electronic health record platform (HCEN), established under Decree 242/017, continues to expand. This digital infrastructure investment increases demand for connected and software-based medical devices, and manufacturers of digital health products should factor Uruguay’s advanced health IT ecosystem into their market assessment, it represents a more receptive environment for SaMD and connected devices than most LATAM markets.

Strategic Tips for Entering the Uruguay Market

To streamline approval and maximize Uruguay market access:

Confirm device classification early under the MERCOSUR four-class framework and review alignment with GMC Resolution 25/21 documentation requirements. Select an experienced Authorized Representative with a demonstrated vigilance infrastructure, not just submission experience. Prepare Spanish labeling and IFU from the outset, as late-stage translation is a common cause of review delays. Ensure ISO 13485 certification is current and GMP documentation is organized for MSP review. Plan ahead for UDI compliance under GMC 07/24, especially for Class III and IV devices. Monitor MERCOSUR updates, particularly GMC 25/21 adoption progress in Uruguay.

Companies already operating in Brazil or Argentina may benefit from documentation harmonization efficiencies under the increasingly aligned MERCOSUR framework. Additionally, manufacturers interested in serving the broader LATAM region should consider Uruguay’s free trade zones and logistics infrastructure, registration in Uruguay combined with regional distribution center positioning can provide an efficient multi-market access model.

U.S. manufacturers have a structural advantage: the United States ranked as the largest supplier of medical equipment to Uruguay in 2024 with 31.4% of total imports, and U.S. ExIm Bank financing products are available to help local healthcare institutions acquire U.S. products and technologies. For U.S. manufacturers, Uruguay’s familiarity with FDA-cleared products, combined with the recognition of foreign registration data under GMC 25/21, creates a more efficient entry pathway than is available in many other LATAM markets.

Conclusion

Uruguay’s medical device regulatory landscape in 2026 is characterized by active MERCOSUR harmonization, phased UDI implementation, and a growing commercial market driven by demographic trends and infrastructure investment. For manufacturers, the most important near-term actions are aligning technical documentation with GMC Resolution 25/21 standards, preparing for UDI compliance under GMC 07/24, and selecting an Authorized Representative with the operational depth to manage both registration and post-market obligations.

Uruguay’s logistics hub positioning, free trade zones, free seaport, free airport, and a pharmaceutical transit flow exceeding $857 million annually, makes it worth evaluating not just as a single market, but as an entry point into broader LATAM distribution. For manufacturers already active in Brazil or Argentina, the marginal cost of Uruguay registration under the increasingly harmonized MERCOSUR framework is lower than entering a standalone market and the logistics infrastructure makes it a natural regional anchor.

How RegDesk Supports Uruguay and MERCOSUR Compliance

RegDesk is an AI-powered Regulatory Information Management System built for medical device manufacturers operating across global markets.

With RegDesk, teams can:

• Track MSP and MERCOSUR regulatory updates in real time
• Prepare and manage structured technical documentation
• Centralize ISO 13485 and GMP records
• Monitor UDI implementation requirements
• Coordinate LATAM submissions
• Manage post-market surveillance and vigilance reporting

As regulatory frameworks across MERCOSUR continue to align, centralized regulatory intelligence is essential to maintain compliance and accelerate market access.

Q&A:

1. Does Uruguay require a locally established Authorized Representative for all medical device registrations? Yes. All manufacturers, importers, and distributors (or their Authorized Representative) must register with MSP. The AR must be locally established in Uruguay, holds the registration, and is legally responsible for regulatory compliance, vigilance reporting, and communication with MSP. A notarized and legalized Power of Attorney is required to appoint the AR. Foreign manufacturers should select an AR with active vigilance management infrastructure, not just submission capability.
2. How long does medical device registration in Uruguay take? Review timelines in Uruguay typically run 6–12 months, varying by device class and the completeness of the submitted dossier. Higher-risk Class III and IV devices may take longer due to additional technical evaluation. Several manufacturers have reported frustration with registration timelines and costs in Uruguay, thorough dossier preparation, complete Spanish labeling, and a Certificate of Free Sale from the country of origin at submission are the most effective ways to minimize delays.
3. How does MERCOSUR GMC Resolution 25/21 affect Uruguay registration? GMC Resolution 25/21, the new MERCOSUR Technical Regulation for the Registration of Medical Products was adopted by Argentina in January 2025, replacing the previous GMC Resolution 40/00. It standardizes classification and documentation requirements across MERCOSUR and introduces recognition of foreign registration data. Uruguay has not yet announced a formal adoption timeline, but manufacturers should prepare documentation aligned with GMC 25/21 standards now to avoid rework as harmonization progresses across the bloc.
4. What are Uruguay’s UDI implementation requirements? Uruguay is implementing UDI in alignment with MERCOSUR Resolution GMC 07/24, phased beginning with higher-risk Class III and IV devices. Manufacturers should prepare UDI carriers on device labeling and monitor MSP guidance for database submission obligations and class-by-class implementation deadlines. Manufacturers already UDI-compliant for FDA or EU markets will find significant overlap in the underlying requirements.
5. Is Uruguay worth pursuing as a standalone market, or primarily as part of a broader MERCOSUR strategy? Both, and the answer depends on your product and commercial strategy. As a standalone market, Uruguay has regulatory complexity relative to its market size, and some manufacturers have opted not to bring their full product suite given registration difficulties and limited market size. However, Uruguay’s free trade zones, free seaport and airport, and regional logistics advantages make it an attractive base for LATAM distribution — and documentation harmonization with Brazil and Argentina submissions reduces the marginal cost of Uruguay registration for manufacturers already active in MERCOSUR’s larger markets.
6. Which unit within Uruguay’s MSP handles medical device registrations? Medical device registrations in Uruguay are handled by the Unidad de Medicamentos y Acreditación de Laboratorios (UNIMED), which sits within the MSP. UNIMED is the operational point of contact for submission queries, registration management, and GMP inspection coordination. Authorized Representatives and manufacturers should direct all pre-submission and registration correspondence to UNIMED specifically.